Bristol-Myers Squibb Co. (BMY) Earns "Hold" Rating from Credit Suisse Group AG


's stock had its "hold" rating reissued by research analysts at Credit Suisse Group AG in a research report issued on Monday. They currently have a $58.00 price objective on the biopharmaceutical company's stock.



from Biotech News